Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Earnings Report 5.163 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

Job openings (Dec.) Factory orders (Dec.) Alphabet Inc (NASDAQ:GOOGL) (Q3) EPS for gain of $2.12, compared to $1.64 in the prior-year quarter. Toyota Motor Corporation (NYSE:TM) (Q3) EPS of $4.36, ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive ...